Nutrition and health

Objectives:
No quantitative assessment has been performed to specifically link the consumption of fruit and vegetables with the incident risk of cognitive disorders. Therefore, this meta-analysis (review article) has been conducted.

Does consumption of fruit and vegetables reduce risk of cognitive disorders?

Study design:
This review article included 6 cohort studies involving a total of 21,175 participants.

Results and conclusions:
The investigators found in pooled analysis that consumption of fruit and vegetables significantly reduced risk of cognitive disorders with 26% [pooled RR = 0.74, 95% BI = 0.62-0.88, I2 = 68%; the significant heterogeneity might be attributed to the ethnic difference].

The investigators concluded that consumption of fruit and vegetables reduces risk of cognitive disorders. However, further large prospective studies should be performed to quantify the potential dose-response patterns of fruit and/or vegetables intake and to explore the role of fruit or vegetables consumption separately on cognitive disorders in different populations.

Original title:
Intake of Fruit and Vegetables and the Incident Risk of Cognitive Disorders: A Systematic Review and Meta-Analysis of Cohort Studies by Wu L, Sun D and Tan Y.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/29188891

Additional information of El Mondo:
Find more information/studies on fruit and vegetables and dementia right here.
 

Objectives:
Currently, dementia is considered untreatable and there are many factors that cause dementia. However, previous studies were unable to identify the factors that affect directly. Therefore, this meta-analysis (review article) has been conducted.

What are the risk factors for prognostic dementia in stroke patients?

Study design:
This review article included 7 hospital-based cohorts of consecutive patients with stroke and 1 population-based cross-sectional study.

Results and conclusions:
The investigators found:
a significantly increased risk of 68% [pooled relative ratio = 1.68, 95% CI = 1.28 to 2.22, I2 = 72%] for atrial fibrillation;
a significantly increased risk of 59% [pooled relative ratio = 1.59, 95% CI = 1.33 to 1.91] for previous stroke;
a significantly increased risk of 40% [pooled relative ratio = 1.40, 95% CI = 1.23 to 1.59, I2% = 14%] for myocardial infarction;
a significantly increased risk of 36% [pooled relative ratio = 1.36, 95% CI = 1.20 to 1.53, I2 = 46%] for hypertension;
a significantly increased risk of 25% [pooled relative ratio = 1.25, 95% CI = 1.11 to 1.41, I2 = 0%] for diabetes mellitus and;
a significantly increased risk of 25% [pooled relative ratio = 1.25, 95% CI = 1.08 to 1.45, I2 = 16%] for previous transient ischemic attack (TIA).

The investigators concluded that strongly risk factors associated with increased risk of post-stroke dementia are atrial fibrillation, previous stroke, myocardial infarction, hypertension, diabetes and previous TIA. However, there are other risk factors related to dementia. Therefore, further studies are needed to investigate and develop the risk score value to forecast the dementia incident in stroke patients.

Original title:
Risk factors associated with post-stroke dementia: a systematic review and meta-analysis by Surawan J, Areemit S, […], Saensak S.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641826/

Additional information of El Mondo:
Find more information/studies on stroke, diabetes, hypertension, dementia and elderly right here.
 

Objectives:
Whole grains are rich source of nutrients and have shown beneficial effects on human health. Therefore, this meta-analysis (review article) has been conducted.

Do taking whole grains reduce mortality risk?

Study design:
This review article included 19 cohort studies with in total 1,041,692 participants and 96,710 deaths.

Results and conclusions:
The investigators found when comparing the highest versus the lowest categories of whole grain, a significantly reduced risk of 16% [RR = 0.84, 95% CI = 0.81-0.88, n = 9] for total mortality.

The investigators found when comparing the highest versus the lowest categories of whole grain, a significantly reduced risk of 17% [RR = 0.83, 95% CI = 0.79-0.86, n = 8] for cardiovascular mortality.

The investigators found when comparing the highest versus the lowest categories of whole grain, a non-significantly reduced risk of 6% [RR = 0.94, 95% CI = 0.87-1.01, n = 14] for cancer mortality.

The investigators found a nonlinear relationship of whole grain intake with risk of total, cardiovascular and cancer mortality.

The investigators found each 28 g/d intake of whole grains was associated with a 9% [pooled RR = 0.91, 95% CI = 0.90-0.93] lower risk for total mortality.

The investigators found each 28 g/d intake of whole grains was associated with a 14% [pooled RR = 0.86, 95% CI = 0.83-0.89] lower risk for cardiovascular mortality.

The investigators found each 28 g/d intake of whole grains was associated with a 3% [pooled RR = 0.97, 95% CI = 0.95-0.99] lower risk for cancer mortality.

The investigators concluded that a higher whole grain intake (at least 28 g/d) reduces risk of total, cardiovascular and cancer mortality. These findings support current dietary guidelines to increase the intake of whole grains. Government officials, scientists and medical staff should take actions to promote whole grains intake.
 
Original title:
Association of whole grain intake with all-cause, cardiovascular, and cancer mortality: a systematic review and dose-response meta-analysis from prospective cohort studies by Zhang B, Zhao Q, [...], Wang X.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/29091078

Additional information of El Mondo:
Find more information/studies on cardiovascular disease and cancer right here.
 

Objectives:
Previous studies had inconsistent findings regarding the association between vitamin C intake and the risk of hip fracture. Therefore, this meta-analysis (review article) has been conducted.

Does taking dietary vitamin C reduce risk of hip fracture?

Study design:
This review article included 6 articles, containing 7908 controls and 2899 cases of hip fracture.

Results and conclusions:
The investigators found when comparing the highest versus the lowest categories of vitamin C, that dietary vitamin C was statistically correlated with a lower risk of 27% for hip fracture [overall OR = 0.73, 95% CI = 0.55-0.97, I2 = 69.1%].

The investigators found that every increment of 50 mg/day dietary vitamin C intake significantly reduced risk of hip fracture with 5% [OR = 0.95, 95% CI = 0.91-1.00, p = 0.05].

The investigators concluded that increasing dietary vitamin C (at least 50 mg/day) intake decreases the risk of hip fracture. In order to verify the association of vitamin C intake and hip fracture risk, further well-designed largely randomized controlled trials (RCTs) are needed.

Original title:
Dietary vitamin C intake and the risk of hip fracture: a dose-response meta-analysis by Sun Y, Liu C, […], Lu Q.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/29101410

Additional information of El Mondo:
Find more information/studies on vitamin C and elderly right here.
 

Objectives:
Fish are a primary source of long-chain omega-3 fatty acids, which may help delay cognitive aging. Therefore, this meta-analysis (review article) has been conducted.

Does a higher fish intake reduce cognitive decline?

Study design:
This review article included 5 cohort studies (23,688 Caucasians aged ≥65 years, 88% female and median follow-up range of 3.9-9.1 years).

Results and conclusions:
The investigators found in multivariate analyses, higher fish intake was associated with slower decline in both global cognition and memory [p-trend ≤ 0.031].

The investigators found consuming ≥4 versus 1 fish serving/week was associated with 0.018 [95% CI = 0.004-0.032] standard units lower rate of memory decline; an effect estimate equivalent to that found for 4 years of age.

The investigators found for global cognition, no comparisons of higher versus low fish intake reached statistical significance.

The investigators found no evidence of effect modification by Alzheimer's.

The investigators concluded that increasing fish intake (at least 4 servings/week) is associated with decreasing memory decline of older persons.

Original title:
Fish intake, genetic predisposition to alzheimer's disease and decline in global cognition and memory in five cohorts of older persons by Samieri C, Morris MC,[…], Grodstein F.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/29053784

Additional information of El Mondo:
Find more information/studies on fish consumption and elderly right here.

A typical serving size of fish can range from 3 to 6 oz., depending on the type of fish and its preparation. The American Heart Association considers 3.5 oz. of cooked fish, or about 3/4 cup, to be a single serving.
 

Objectives:
With an aging population and no cure for dementia on the horizon, risk factor modification prior to disease onset is an urgent health priority. Therefore, this meta-analysis (review article) has been conducted.

What is the effect of low vitamin D status or vitamin D supplementation on cognition in midlife and older adults without a diagnosis of dementia?

Study design:
This review article included 26 observational (cross-sectional and longitudinal cohort) studies and 3 intervention studies (n = 19-9,556).

Results and conclusions:
The investigators found in 26 observational studies that low vitamin D status was associated with worse cognitive performance [OR = 1.24, CI = 1.14-1.35] and cognitive decline [OR = 1.26, CI = 1.09-1.23] in midlife and older adults without a diagnosis of dementia; with cross-sectional yielding a stronger effect compared to longitudinal studies.

However, the investigators found in 3 intervention studies that vitamin D supplementation showed no significant benefit on cognition compared with control [SMD = 0.21, CI = -0.05 to 0.46].

The investigators concluded that observational evidence demonstrates low vitamin D is related to poorer cognition in midlife and older adults without a diagnosis of dementia; however, interventional studies are yet to show a clear benefit from vitamin D supplementation. From the evidence to date, there is likely a therapeutic age window relevant to the development of disease and therefore vitamin D therapy. Longitudinal lifespan studies are necessary to depict the optimal timing and duration in which repletion of vitamin D may protect against cognitive decline and dementia in aging, to better inform trials and practice towards a successful therapy.

Original title:
A Systematic Review and Meta-Analysis of The Effect of Low Vitamin D on Cognition by Goodwill AM and Szoeke C.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/28758188

Additional information of El Mondo:
Find more information/studies on vitamin D, review article/significant, elderly and dementia right here.
 

Objectives:
Many publications have investigated the association between metal ions and the risk of Alzheimer's disease (AD), but the results were ambiguous. Therefore, this meta-analysis (review article) has been conducted.

What is the association between serum copper/zinc/iron levels and Alzheimer's disease risk?

Study design:
This review article included 44 case-control studies.

Results and conclusions:
The investigators found in 35 case-control studies (2,128 Alzheimer's disease patients and 2,889 healthy controls. The mean age of the patient groups was >54), that serum copper levels were significant higher in Alzheimer's disease patients [MD = 9.13, 95% CI = 6.17 to 12.09, p 0.00001].

The investigators found in 22 case-control studies (1,027 Alzheimer's disease patients and 1,949 healthy controls. The mean age of the patient groups was >54), that serum zinc levels were significant lower in Alzheimer's disease patients [MD = -7.80, 95% CI = -11.61 to -3.99, p 0.0001].

The investigators found in 25 case-control studies (1,379 Alzheimer's disease patients and 1,664 healthy controls. The mean age of the patient groups was >62.74), that serum iron levels were significant lower in Alzheimer's disease patients [MD = -13.01, 95% CI = -20.75 to -5.27, p = 0.001].

The investigators concluded that serum copper levels are significantly increased, while serum zinc/iron levels are significantly decreased in Alzheimer's disease patients.

Original title:
Serum Copper, Zinc, and Iron Levels in Patients with Alzheimer's Disease: A Meta-Analysis of Case-Control Studies by Li DD, Zhang W, [...], Zhao P.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605551/

Additional information of El Mondo:
Find more information/studies on copper, zinc, iron and dementia right here.
 

Objectives:
Does breastfeeding reduce risk of endometrial cancer?

Study design:
This review article included individual-level data from 3 cohort and 14 case-control studies, with a total of  8,981 women with endometrial cancer and 17,241 women in a control group.

Results and conclusions:
The investigators found ever breastfeeding was associated with an 11% reduction in risk of endometrial cancer [pooled OR = 0.89, 95% CI = 0.81-0.98].
The association with ever breastfeeding was not explained by greater parity and did not vary notably by body mass index or histologic subtype (grouped as endometrioid and mucinous compared with serous and clear cell).

The investigators found longer average duration of breastfeeding per child was associated with lower risk of endometrial cancer, although there appeared to be some leveling of this effect beyond 6-9 months.

The investigators concluded that reducing endometrial cancer risk can be added to the list of maternal benefits associated with breastfeeding. Ongoing promotion, support and facilitation of this safe and beneficial behavior might therefore contribute to the prevention of this increasingly common cancer.

Original title:
Breastfeeding and Endometrial Cancer Risk: An Analysis From the Epidemiology of Endometrial Cancer Consortium by Jordan SJ, Na R, […], Webb PM.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/28486362

Additional information of El Mondo:
Find more information/studies on cancer and pregnancy right here.
 

Objectives:
Whether iron is associated with the development of gestational diabetes mellitus (GDM) is not clear. Therefore, this review article (meta-analysis) has been conducted.

Do increased dietary intake of iron and body iron status increase risk of gestational diabetes mellitus in pregnant women? 

Study design:
This review article included 12 case-control  studies, 9 cohort studies and  2  randomized  controlled  studies (RCT) with in total, 3,034 gestational diabetes mellitus pregnant women and 26,344 non-gestational diabetes mellitus pregnant women.

Results and conclusions:
The investigators found high dietary intake of heme iron was significantly associated with a 65% gestational diabetes mellitus risk [RR = 1.65, 95% CI = 1.28 to 2.12, I2 = 0%].

The investigators found for each 1 mg/day increment of dietary heme iron intake a significantly 38% gestational diabetes mellitus risk [RR = 1.38, 95% CI = 1.19 to 1.61, I2 = 0%].

The investigators found higher body iron stores, as represented by serum ferritin level, were correlated with a significantly increased gestational diabetes mellitus risk of 64% [RR = 1.64, 95% CI = 1.27 to 2.11, I2% = 7%].

The investigators found no association between gestational diabetes mellitus and the intakes of nonheme iron, total iron or supplemental iron.

The investigators concluded increased dietary intake of heme iron (at least 1 mg/day) and body iron status are positively associated with the risk of gestational diabetes mellitus development in pregnant women. Future studies are warranted to better understand the role of iron in gestational diabetes mellitus development.

Original title:
Dietary intake of heme iron and body iron status are associated with the risk of gestational diabetes mellitus: a systematic review and meta-analysis by Zhao L, Lian J, [...], Wang F.

Link:
http://apjcn.nhri.org.tw/server/APJCN/26/6/1092.pdf

Additional information of El Mondo:
Find more information/studies on iron, pregnancy and review article/significant/95% CI right here.

Gestational diabetes mellitus is a condition in which a woman without diabetes develops high blood sugar levels during pregnancy. Gestational diabetes mellitus affects between 2% and 5% of pregnant women.

Objectives:
Available studies in the literature on the selenium levels in Alzheimer's disease (AD) are inconsistent with some studies reporting its decrease in the circulation, while others reported an increase or no change as compared to controls. Therefore, this meta-analysis (review article) has been conducted.

Do lower circulatory (plasma/serum and blood), erythrocyte and cerebrospinal fluid (CSF) selenium levels increase Alzheimer's disease risk?

Study design:
This review article included 12 case-control/observational studies reporting selenium concentrations in Alzheimer's disease and controls.

Results and conclusions:
The investigators found random-effects meta-analysis indicated a decrease in circulatory [SMD = -0.44], erythrocellular [SMD = -0.52] and cerebrospinal fluid [SMD = -0.14] selenium levels in Alzheimer's disease patients compared to controls

The investigators found stratified meta-analysis demonstrated that the selenium levels were decreased in both the subgroups with [SMD = -0.55] and without [SMD = -0.37] age matching between Alzheimer's disease and controls.

The investigators also found a direct association between decreased selenium levels and glutathione peroxidase (GPx) in Alzheimer's disease.

The investigators concluded that circulatory selenium concentration is significantly lower in Alzheimer's disease patients compared to controls and this decrease in selenium is directly correlated with an important antioxidant enzyme, the glutathione peroxidase, in Alzheimer's disease.

Original title:
A systematic review and meta-analysis of the circulatory, erythrocellular and CSF selenium levels in Alzheimer's disease: A metal meta-analysis (AMMA study-I) by Reddya VS, Bukkeb S, […], Pandeye AK.

Link:
http://www.sciencedirect.com/science/article/pii/S0946672X1630205X%20

Additional information of El Mondo:
Find more information/studies on selenium and dementia right here.
 

Objectives:
Does higher protein intake increase bone mineral density?

Study design:
This review article included 6 RCTs and 20 prospective cohort studies.
There were no adverse effects of higher protein intakes.
Studies were heterogeneous and confounding could not be excluded.

Results and conclusions:
The investigators found moderate evidence suggested that higher protein intake may have a protective effect on lumbar spine bone mineral density compared with lower protein intake [net percentage change = 0.52%, 95% CI = 0.06%-0.97%, I2 = 0%, n = 5] but had no effect on total hip, femoral neck, or total body bone mineral density or bone biomarkers.

The investigators concluded that higher protein intake may have a protective effect on lumbar spine bone mineral density. May have because studies were heterogeneous and confounding could not be excluded. Therefore, high-quality, long-term studies are needed to clarify dietary protein's role in bone health.

Original title:
Dietary protein and bone health: a systematic review and meta-analysis from the National Osteoporosis Foundation by Shams-White MM, Chung M, […], Weaver CM.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/28404575

Additional information of El Mondo:
Find more information/studies on protein and elderly right here.

A higher protein diet is a diet with 20-35 En% protein. The easiest way to meet a diet with 20-35 En% protein is to choose food items/meals with also 20-35 En% protein. Check here which products contain 20-35 En% protein.
 

Objectives:
The association between vitamin D deficiency and early spontaneous pregnancy loss (SPL) is unclear. Therefore, this review article (meta-analysis) has been conducted.

Does a vitamin D deficiency increase risk of early spontaneous pregnancy loss?

Study design:
This review article included 5 studies (case-control and cohort studies), including 10,630 pregnant women.

Results and conclusions:
The investigators found no significant association between a low 25(OH)D level (vitamin D level in blood) and an increased risk of early spontaneous pregnancy loss.

However, the investigators found in subgroup analysis, an extremely low 25(OH)D level (20 ng/mL) was significantly associated with an 124% increased risk of early spontaneous pregnancy loss in the first trimester [relative risk = 2.24, 95% CI = 1.15-4.37, I2 = 0.0%, p = 0.355].

The investigators concluded that severe vitamin D deficiency (20 ng/mL) could be detrimental to early embryonic development and increases risk of early spontaneous pregnancy loss.

Original title:
Meta-analysis of the effect of the maternal vitamin D level on the risk of spontaneous pregnancy loss by Zhang H, Huang Z, [...], Wei Y.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/28500757

Additional information of El Mondo:
Find more information/studies on vitamin D, pregnancy and review article/significant/95% CI right here.

Objectives:
Are there differences in serum ceruloplasmin levels between patients with preeclampsia and healthy controls?

Study design:
This review article included 15 studies, with a total number of 1927 women.

Results and conclusions:
The investigators found that maternal serum ceruloplasmin concentration was significantly higher in preeclamptic than in the healthy pregnant women [MD = 12.57 mg/dL, 95% CI = 8.81 to 16.33].

The investigators found that ceruloplasmin levels were significantly higher both in mild [MD = 13.8 mg/dL, 95% CI = 2.64 to 23.53] and severe [MD = 21.84 mg/dL, 95% CI = 0.97 to 42.71] preeclampsia, when compared to the control group.

The investigators found that the severity of the disease did not significantly affect the levels of protein [MD = -9.34 mg/dL, 95% CI = -20.93 to 2.26].

The investigators concluded that serum ceruloplasmin may be a useful screening and follow-up tool for the evaluation of pregnant women with an indicative history of developing preeclampsia. Future studies are needed to evaluate the levels of this specific protein throughout the pregnancy course and provide data on its sensitivity and specificity by introducing cut-off values.

Original title:
Serum ceruloplasmin levels in preeclampsia: a meta-analysis by Bellos I, Papantoniou N and Pergialiotis V.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/28605950

Additional information of El Mondo:
Find more information/studies on copper, pregnancy and review article/significant/95% CI right here.

Ceruloplasmin carries 65% to 90% of the copper found in blood.

Objectives:
Current studies evaluating the association of tea consumption and bone mineral density (BMD) have yielded inconsistent findings. Therefore, this meta-analysis (review article) has been conducted.

Does tea consumption increase bone mineral density?

Study design:
This review article included 4 cohort, 1 case-control and 8 cross-sectional studies including a total of 12,635 cases (6,059 in the tea consumption group and 6,576 individuals in non-tea consumption group).

Results and conclusions:
The investigators found tea consumption significantly reduced the occurrence of low bone mass with 34% [OR  =  0.66, 95% CI  =  0.47-0.94, p =  0.02].

The investigators found tea consumption significantly yielded higher mineral densities in several bones, including:
-the lumbar spine [standardized mean difference (SMD) = 0.19, 95% CI = 0.08-0.31, p  =  0.001];
-hip [SMD = 0.19, 95% CI = 0.05-0.34, p  =  0.01];
-femoral neck [mean difference (MD) = 0.01, 95% CI = 0.00-0.02, p  =  0.04];
-Ward triangle [MD = 0.02, 95% CI = 0.01-0.04, p  =  0.001] and;
-greater trochanter [MD = 0.03, 95% CI = 0.02-0.04, p  0.00001]
than the non-tea consumption group.

The investigators concluded that tea consumption increases bone mineral density, especially in the lumbar spine, hip, femoral neck, Ward triangle and greater trochanter, which can prevent bone loss.

Original title:
Updated association of tea consumption and bone mineral density: A meta-analysis by Zhang ZF, Yang JL, [...], Liu ZX.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371490/

Additional information of El Mondo:
Find more information/studies on tea consumption and elderly right here.
 

Objectives:
Is there a relationship between serum 25(OH)D (vitamin D blood level) and mortality risk in the general population?

Study design:
This review article included 14 prospective cohort studies that involved 5562 deaths out of 62548 individuals.
In the parametric model, which is based on 11 studies and 59231 individuals, the lowest quantile as the reference category has been used.

Evidence of heterogeneity for the RR was apparent when highest were compared with lowest categories [p = 0.008, I2 = 58%].

There was no evidence of publication bias.

Results and conclusions:
The investigators found for “highest compared with lowest” categories of 25(OH)D, a significant reduced risk of 29% for mortality [RR = 0.71, 95% CI = 0.50-0.91].

The investigators found in the parametric model, the estimated summary RRs of mortality were 0.86 [95% CI = 0.82-0.91], 0.77 [95% CI = 0.70-0.84] and 0.69 [95% CI = 0.60-0.78] for individuals with an increase of 12.5, 25 and 50 nmol 25(OH)D serum values/L, respectively, from a median reference category of ∼27.5 nmol/L.
However, no significant decrease in mortality was found above ∼87.5 nmol/L.

The investigators concluded there is a nonlinear decrease in mortality risk as circulating 25(OH)D increases, with optimal concentrations ∼75-87.5 nmol/L. Because many adults do not achieve these 25(OH)D values, large prospective randomized trials are urgently needed to investigate whether vitamin D supplementation is able to reduce mortality risk in the general population.

Original title:
Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies by Zittermann A, Iodice S, [...], Gandini S.

Link:
http://ajcn.nutrition.org/content/95/1/91.full

Additional information of El Mondo:
Find more information/studies on vitamin D right here. 

Objectives:
Epidemiological studies evaluating the associations between serum copper and ratios of copper/zinc (Cu/Zn) and the preeclampsia (PE) risk in Asian population have produced inconsistent results. Therefore, this review article (meta-analysis) has been conducted.

Do a higher serum copper and ratios of Cu/Zn increase the preeclampsia risk in Asian population?

Study design:
This review article included relevant studies up to November 2016.
Pooled standardized mean difference (SMD) was calculated with random effects model.

Results and conclusions:
The investigators found that preeclampsia patients significantly had a higher serum copper level [SMD = 1.05, 95% CI = 0.34 to 1.77, I2 = 96.9%, p 0.0001] compared with healthy pregnancy controls.

The investigators found in subgroup analyses, a higher serum copper level in preeclampsia patients was observed in case-control studies [SMD = 1.39, 95% CI = 0.44 to 2.34]. However, no significant difference was found between preeclampsia patients and healthy pregnancy controls for ratios of Cu/Zn [SMD = 0.26, 95% CI = -0.77 to 1.29, I2 = 95.8%, p 0.0001].

The investigators concluded that a higher serum copper level is associated with an increased risk of preeclampsia in Asian population. However, further studies are needed to confirm these results.

Original title:
High serum copper level is associated with an increased risk of preeclampsia in Asians: A meta-analysis by Song X, Li B, [...], Zhang D.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/28385285

Additional information of El Mondo:
Find more information/studies on copper, zinc, pregnancy and review article/significant/95% CI right here.

Objectives:
Does soy isoflavone reduce the frequency and severity of hot flashes?

Study design:
This review article included 19 trials (13 included hot flash frequency, of which 10 for severity and 3 for composite scores).
17 trials were selected for meta-analyses to clarify the effect of soybean isoflavones on hot flash frequency (13 trials) and severity (9 trials).

Results and conclusions:
The investigators found intake of soy isoflavones (median = 54 mg aglycone equivalents) for 6 weeks to 12 months significantly reduced the frequency (combined fixed-effect and random effects model) of hot flashes by 20.6% [95% CI = -28.38 to -12.86, p 0.00001] compared with placebo [p heterogeneity = 0.0003, I2 = 67% for random effects model].

The investigators also found isoflavones significantly reduced hot flash severity by 26.2% [95% CI = -42.23 to -10.15, p = 0.001] compared with placebo [p heterogeneity 0.00001, I2 = 86% for random effects model].

The investigators found isoflavone supplements providing more than 18.8 mg of genistein (the median for all studies) were more than twice as potent at reducing hot flash frequency than lower genistein supplements.

The investigators concluded soy isoflavone supplements (54 mg per day for 6 weeks to 12 months), derived by extraction or chemical synthesis, are significantly more effective than placebo in reducing the frequency and severity of hot flashes. Additional studies are needed to further address the complex array of factors that may affect efficacy, such as dose, isoflavone form, baseline hot flash frequency and treatment duration.

Original title:
Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials by Taku K, Melby MK, […], Messina M.

Link:
http://journals.lww.com/menopausejournal/Abstract/2012/07000/Extracted_or_synthesized_soybean_isoflavones.11.aspx

Additional information of El Mondo:
Find more studies/information on elderly and isoflavones right here.
 

Objectives:
Zinc sulfate may be a promising approach to treat neonatal jaundice. However, the results remain controversial. Therefore, this review article (meta-analysis) has been conducted.

Does zinc sulfate supplementation reduce neonatal jaundice?

Study design:
This review article included 5 RCTs involving 645 patients.

Results and conclusions:
The investigators found overall, compared with placebo, zinc sulfate supplementation failed to significantly reduce total serum bilirubin on 3 days [mean difference = 0.09 mg/dL, 95% CI = -0.49 to 0.67, p = 0.77]. Non-significant because p-value of 0.77 was greater than p-value of 0.05.

The investigators found overall, compared with placebo, zinc sulfate supplementation failed to significantly reduce total serum bilirubin on 7 days [mean difference= -0.37 mg/dL, 95% CI= -98 to 0.25, p  = 0.25].

The investigators found overall, compared with placebo, zinc sulfate supplementation failed to significantly reduce the incidence of hyperbilirubinemia [OR = 1.14, 95% CI = 0.74 to 1.76, p = 0.56].

The investigators found overall, compared with placebo, zinc sulfate supplementation showed no influence on phototherapy requirement [OR = 0.90, 95% CI = 0.41 to 1.98, p = 0.79]. Non-significant because OR of 1 was found in the OR of 0.41 to 1.98. OR of 1 means no risk/association.

The investigators found overall, compared with placebo, zinc sulfate supplementation significantly decreased duration of phototherapy [mean difference = -16.69 h, 95% CI = -25.09 to -8.3 h, p 0.000].

The investigators concluded zinc sulphate supplementation does not reduce the total serum bilirubin on 3 days and 7 days, the incidence of hyperbilirubinemia and phototherapy requirement, but significantly decreases duration of phototherapy.

Original title:
The influence of zinc sulfate on neonatal jaundice: a systematic review and meta-analysis by Yang L, Wu, [...], Tang J.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/28372469

Additional information of El Mondo:
Find more information/studies on pregnancy and zinc right here.

Neonatal jaundice occurs when a baby has a high level of bilirubin in the blood. Bilirubin is a yellow substance that the body creates when it replaces old red blood cells. The liver helps break down the substance so it can be removed from the body in the stool.

A high level of bilirubin makes a baby's skin and whites of the eyes look yellow. This is called neonatal jaundice.

Jaundice is a common and usually harmless condition in newborn babies.
The symptoms of neonatal jaundice usually develop 2 to 3 days after the birth and tend to get better without treatment by the time the baby is about 2 weeks old.

Objectives:
There is an ongoing debate on the involvement of systemic copper (Cu) dysfunctions in Alzheimer's disease (AD) and clinical studies comparing Cu levels in serum, plasma and cerebrospinal fluid (CSF) of AD patients with those of healthy controls have delivered non-univocal and often conflicting results. Therefore, this review article has been conducted.

Does blood level of copper increase in Alzheimer’s disease?

Study design:
This review article included 26 studies including a pooled total of 761 AD subjects and 664 controls for serum Cu studies, 205 AD subjects and 167 controls for plasma Cu and of 116 AD subjects and 129 controls for CSF Cu.

Results and conclusions:
The investigators found Alzheimer's disease patients have higher levels of serum copper than healthy controls. Plasma data did not allow conclusions, due to their high heterogeneity, but the meta-analysis of the combined serum and plasma studies confirmed higher copper levels in Alzheimer's disease patients. 

The investigators found the analysis of CSF data revealed no difference between Alzheimer's disease patients and controls.

The investigators concluded Alzheimer's disease patients have higher levels of serum and plasma copper than healthy controls.

Original title:
Copper in Alzheimer's disease: a meta-analysis of serum, plasma, and cerebrospinal fluid studies by Bucossi S, Ventriglia M, […], Squitti R.

Link:
http://www.ncbi.nlm.nih.gov/pubmed/21187586

Additional information of El Mondo:
Find more information/studies on copper and dementia right here.

Objectives:
The association between dietary vitamin K intake and the risk of fractures is controversial. Therefore, this meta-analysis (review article) has been conducted.

Does dietary vitamin K intake reduce risk of fractures?

Study design:
This review article included 4 cohort studies and 1 nested case-control study, including 80,982 total subjects and 1114 fracture cases.

The fractures were assessed using confirmed self-reported, medical and radiological report. Dietary vitamin K intake was assessed with a food-frequency questionnaire (FFQ) in 4 studies, only 1 study used 4-day or 7-day food record.
Vitamin K intake in all included studies refers exclusively to the intake of phylloquinone (vitamin K1), which is the predominant form of vitamin K in foods.
All subjects were more than 30 years old.
Duration of follow-up for the included studies ranged from 6.9 to 10 years.
Most studies provided RRs that were adjusted for age, BMI, BMD, physical activity, vitamin D and calcium intake, smoking and alcohol consumption.

The Begg and Egger tests did not show any substantial asymmetry (p  =  0.50 for Begg test and p  =  0.32 for Egger tests). Further trim and filled meta-analysis showed that there were no trimming data added.

Results and conclusions:
The investigators found for highest vs. the lowest dietary vitamin K intake a significant reduced risk of 22% [RR = 0.78, 95% CI = 0.56-0.99, I2  =  59.2%, p  = 0 .04] for fractures.

The investigators found for every increment of 50μg dietary vitamin K intake per day a significant reduced risk of 3% [RR  = 0.97, 95% CI = 0.95-0.99, I2  =  25.9%, p  = 0 .25] for fractures.

The investigators found a significant reduced risk of 24% [RR = 0.76, 95% CI = 0.58-0.93, I2  =  59.2%, p  = 0 .04] for fractures in studies with more than 10 years of follow-up.

The investigators concluded that higher dietary vitamin K intake; at least 50μg dietary vitamin K intake per day decreases the risk of fractures. This review article offers additional evidence on the relationship between dietary vitamin K intake and risk of fractures. The benefit of vitamin K should be confirmed in future well-designed prospective cohort studies and clinical trials.

Original title:
Vitamin K intake and the risk of fractures: A meta-analysis by Hao G, Zhang B, [...], Cao X.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413254/

Additional information of El Mondo:
Find more information/studies on vitamin K and elderly right here.
 

Objectives:
In view of the vital role of oxidative stress in the pathogenesis of Alzheimer's disease (AD), the potential of antioxidant supplements to prevent AD have gained much interest, while there are conflicting results on this topic in recent years. Therefore, this review article has been conducted.

Does dietary intake of vitamin C and E and β-carotene decrease risk of Alzheimer's disease?

Study design:
This review article included 7 articles (dietary intake, but no supplements).

Results and conclusions:
The investigators found a significant decreased risk for Alzheimer disease of 24% [pooled relative risk = 0.76 95% CI = 0.67-0.84] for dietary intake of vitamin E and of 17% [pooled relative risk = 0.83, 95% CI = 0.72-0.94] for dietary intake of vitamin C.

However, the investigators found a non-significant decreased risk of 12% [pooled relative risk = 0.88, 95% CI = 0.73-1.03] for dietary intake of β-carotene.

The investigators concluded dietary intakes of vitamin C and E lower the risk of Alzheimer's disease, with vitamin E exhibiting the most pronounced protective effects. The findings will be of significance to the prevention and interventional treatment of Alzheimer's disease.

Original title:
Dietary intakes of vitamin E, vitamin C, and β-carotene and risk of Alzheimer's disease: a meta-analysis by Li FJ, Shen L and Ji HF.

Link:
http://www.ncbi.nlm.nih.gov/pubmed/22543848

Additional information of El Mondo:
Find more information/studies on vitamin C and E and carotenoids right here. 

Objectives:
Manganese (Mn) is one of the most studied environmental heavy metals linked to Alzheimer’s disease (AD). However, it remains unclear whether serum manganese levels are associated with Alzheimer’s disease and mild cognition impairment (MCI, a prodromal stage of AD). Therefore, this meta-analysis (review article) has been conducted.

Does a lower serum manganese level increase risk of cognitive decline?

Study design:
This review article included 17 studies, involving 836 cases and 1254 health controls (HC).

The sample size of the included studies ranged from 8 to 758. The average age of the patient groups ranged from 66.2 to 87.0 years. The proportion of female patients ranged from 33% to 80%.

Strong heterogeneity existed among the studies. Heterogeneity was not due to methods for measuring manganese levels, geographic locations, age and gender of patients.

There was no publication bias in the present meta-analysis evaluated by the Egger’s test (p = 0.258) and Begg’s test (p = 0.107).

Results and conclusions:
The investigators found random-effects meta-analysis showed that patients with Alzheimer’s disease had significantly reduced serum manganese levels compared with health control subjects [SMD = -0.39, 95% CI = -0.71 to -0.08, p = 0.015].

The investigators found mild cognition impairment individuals had a tendency toward reduced serum manganese levels compared with health control subjects [SMD = -0.31, 95% CI = -0.70 to 0.08, p = 0.117].

The investigators found a significant decrease in serum manganese levels in patients with cognitive impairment (including both AD patients and MCI patients) [SMD = -0.37, 95% CI = -0.60 to -0.13, p = 0.002].

The investigators found no significant differences between Alzheimer’s disease and mild cognition impairment patients in serum levels [SMD = 0.24, 95% CI = -0.23 to 0.72, p = 0.310].

The investigators concluded that the serum manganese levels are lower in Alzheimer’s disease patients and manganese deficiency may be a risk factor for Alzheimer’s disease. However, the results should be interpreted with caution due to the high heterogeneity of the studies.

Original title:
Association of Serum Manganese Levels with Alzheimer’s Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis by Du K, Liu M, [...], Wei M.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372894/

Additional information of El Mondo:
Find more information/studies on manganese and elderly right here.
 

Objectives:
Lutein and zeaxanthin are thought to have beneficial effects on protecting the lens against cataract formation, but findings from epidemiologic studies have been inconsistent. Therefore, this review article has been conducted.

Does dietary lutein and zeaxanthin intake reduce age-related cataract risk?

Study design:
This review article included 6 prospective cohort studies, involving 4416 cases and 41999 participants.

Results and conclusions:
The investigators found for comparing the highest with the lowest categories of dietary lutein and zeaxanthin intake, a significant reduced risk for nuclear cataract of 25% [RR = 0.75, 95% CI = 0.65-0.85], but the reduced risk was not significant for cortical cataract [RR = 0.85, 95% CI = 0.53-1.17] and for posterior subcapsular cataract [RR = 0.77, 95% CI = 0.40-1.13]. Significant means, there is an association with a 95% confidence.

The investigators found in dose-response analysis that every 300 μg/d increment in dietary lutein and zeaxanthin intake was significantly associated with a 3% [RR = 0.97, 95% CI = 0.94-0.99] reduction in the risk of nuclear cataract.

The investigators found in dose-response analysis that every 300 μg/d increment in dietary lutein and zeaxanthin intake was non-significantly associated with a 1% [RR = 0.99, 95% CI = 0.95-1.02] reduction in the risk of cortical cataract. Non-significantly means, there is no association with a 95% confidence.

The investigators found in dose-response analysis that every 300 μg/d increment in dietary lutein and zeaxanthin intake was non-significantly associated with a 3% [RR = 0.97, 95% CI = 0.93-1.01] reduction in the risk of posterior subcapsular cataract. Non-significantly because RR of 1 was found in 95% CI of 0.93 to 1.01. RR of 1 means no risk.

The investigators concluded dietary lutein and zeaxanthin intake (at least 300 μg/d) is associated with a reduced risk of age-related cataract, especially nuclear cataract in a dose-response manner, indicating a beneficial effect of lutein and zeaxanthin in age-related cataract prevention.

Original title:
A dose–response meta-analysis of dietary lutein and zeaxanthin intake in relation to risk of age-related cataract by Ma L, Hao ZX, [...], Pan JP.

Link:
http://link.springer.com/article/10.1007/s00417-013-2492-3

Additional information of El Mondo:
Find more studies/information on elderly right here.

Objectives:
Hormonal effects of soy and isoflavones have been investigated in numerous trials with equivocal findings. Therefore, this review article has been conducted.

What are hormonal effects of soy and isoflavones in both pre- and postmenopausal women?

Study design:
This review article included 47 (11 of pre-, 35 of post- and 1 of perimenopausal women) randomized or residential crossover trials of soy or isoflavones for 4 or more weeks on estrogens, SHBG, FSH, LH, progesterone and thyroid hormones in women was assessed independently in duplicate.

The studies ranged from 4 to 104 weeks long: 29 were 4-12 weeks in duration, 9 were 13-26 weeks, 7 were 27-52 weeks and 2 were >1 year.

Results and conclusions:
The investigators found in premenopausal women, soy or isoflavone consumption did not affect primary outcomes estradiol, estrone or SHBG concentrations, but significantly reduced secondary outcomes FSH and LH [by approximately 20% using standardized mean difference (SMD), p = 0.01 and p = 0.05, respectively].

The investigators found in 10 studies that soy or isoflavone consumption increased menstrual cycle length by 1.05 days [95% CI = 0.13-1.97].

The investigators found in post-menopausal women, soy or isoflavone consumption had no statistically significant effects on estradiol, estrone, SHBG, FSH or LH, although there was a small statistically non-significant increase in total estradiol with soy or isoflavones [by approximately 14% using standardized mean difference (SMD), p = 0.07, 21 studies].

The investigators concluded isoflavone-rich soy products decrease FSH and LH in premenopausal women and may increase estradiol in post-menopausal women. The clinical implications of these modest hormonal changes remain to be determined.

Original title:
Effects of soy protein and isoflavones on circulating hormone concentrations in pre- and post-menopausal women: a systematic review and meta-analysis by Hooper L, Ryder JJ, […], Cassidy A.

Link:
http://humupd.oxfordjournals.org/content/15/4/423.full

Additional information of El Mondo:
Find about studies/information on elderly and soy right here.

 

Objectives:
Does iron supplementation during pregnancy improve maternal haematological status and birth weight?

Study design:
This review article included 48 RCTs (17,793 women) and 44 cohort studies (1,851,682 women).

The dose of iron in RCTs ranged from 10 mg to 240 mg daily. Duration of supplementation varied from 7 to 8 weeks up to 30 weeks during pregnancy.

Significant heterogeneity existed for several outcomes that could not be explained substantially by pre-specified subgroups.

Results and conclusions:
The investigators found iron supplementation during pregnancy increased maternal mean haemoglobin concentration by 4.59 g/L [95% CI = 3.72 to 5.46] compared with controls.

The investigators found iron with folic acid was associated with a significant increase in mean haemoglobin concentration of 10.41 g/L [95% CI = 5.36 to 15.46, I2 = 0%, 9 trials] and reduction in risk of anaemia in the third trimester or at delivery of 56% [95% CI = 0.37 to 0.53, I2 = 44%, 5 trials]. Significant means there is an association with a 95% confidence.

The investigators found iron supplementation during pregnancy significantly reduced the risk of anaemia with 50% [95% CI = 0.42 to 0.59] compared with controls.

The investigators found iron supplementation during pregnancy significantly reduced the risk of iron deficiency (of the mother) with 41% [95% CI = 0.46 to 0.79] compared with controls.

The investigators found iron supplementation during pregnancy significantly reduced the risk of iron deficiency anaemia with 60% [95% CI = 0.26 to 0.60] compared with controls.

The investigators found iron supplementation during pregnancy significantly reduced the risk of low birth weight (2500 g) with 19% [95% CI = 0.71 to 0.93] compared with controls.

However, the investigators found iron supplementation during pregnancy non-significantly reduced the risk of preterm birth with 16% [95% CI = 0.68 to 1.03] compared with controls. Non-significant means there is no association with a 95% confidence.

The investigators found in cohort studies that anaemia in the first or second trimester was significantly associated with a higher risk for low birth weight of 29% [adjusted odds ratio 1.29, 95% CI = 1.09 to 1.53] and preterm birth with 21% [adjusted odds ratio = 1.21, 95% CI = 1.13 to 1.30].

The investigators found in exposure-response analysis that for every 10 mg increase in iron dose/day, up to 66 mg/day, the relative risk of maternal anaemia was significantly 0.88 [95% CI = 0.84 to 0.92, p for linear trend 0.001].

The investigators found in exposure-response analysis that birth weight increased by 15.1 g [95% CI = 6.0 to 24.2, p for linear trend = 0.005] and risk of low birth weight significantly decreased by 3% [relative risk = 0.97, 95% CI = 0.95 to 0.98, p for linear trend 0.001] every 10 mg increase in dose/day.

Furthermore, the investigators found for each 1 g/L increase in mean haemoglobin, birth weight increased by 14.0 g [95% CI = 6.8 to 21.8, p for linear trend = 0.002]. However, mean haemoglobin was not associated with the risk of low birth weight and preterm birth.

The investigators found no evidence of a significant effect on duration of gestation, small for gestational age births and birth length and duration of iron use was not significantly associated with the outcomes after adjustment for dose.

The investigators concluded daily prenatal use of iron substantially improved birth weight in a linear dose-response fashion, probably leading to a reduction in risk of low birth weight. An improvement in prenatal mean haemoglobin concentration linearly increased birth weight and a linear decrease in maternal anaemia with higher doses of iron, up to 66 mg/day.

Original title:
Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: systematic review and meta-analysis by Haider BA, Olofin I, […], Fawzi WW.

Link:
http://www.bmj.com/content/346/bmj.f3443

Additional information of El Mondo:
Find more information/studies on iron and pregnancy right here.

Iron deficiency anaemia occurs when there isn't enough iron in the body. Anaemia is a condition where the amount of haemoglobin in the blood is below the normal level.
Iron deficiency anaemia has been defined as haemoglobin 110 g/L and serum ferritin 12 µg/L.